Summary
An effective monotherapy to target the complex and multifactorial pathology of SARS-CoV-2 infection poses a challenge to drug repositioning, which can be improved by combination therapy. We developed an online network pharmacology-based drug repositioning platform, COVID-CDR (http://vafaeelab.com/COVID19repositioning.html), that enables a visual and quantitative investigation of the interplay between the primary drug targets and the SARS-CoV-2-host interactome in the human protein-protein interaction network. COVID-CDR prioritizes drug combinations with potential to act synergistically through different, yet potentially complementary, pathways. It provides the options for understanding multi-evidence drug-pair similarity scores along with several other relevant information on individual drugs or drug pairs. Overall, COVID-CDR is a first-of-its-kind online platform that provides a systematic approach for pre-clinical in silico investigation of combination therapies for treating COVID-19 at the fingertips of the clinicians and researchers.
【저자키워드】 DSML 3: Development/Pre-production: Data science output has been rolled out/validated across multiple domains/problems, 【초록키워드】 pathology, SARS-COV-2 infection, combination therapy, drug, in silico, drug target, information, monotherapy, Quantitative, platform, protein-protein interaction, Pathways, similarity, complementary, complex, drug combination, treating COVID-19, multifactorial, approach, effective, provide, clinicians and researchers, 【제목키워드】 COVID-19, resource, mechanism of action,